Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers...

Full description

Saved in:
Bibliographic Details
Main Authors: Nai-Jia Huang, Novalia Pishesha, Jean Mukherjee, Sicai Zhang, Rhogerry Deshycka, Valentino Sudaryo, Min Dong, Charles B. Shoemaker, Harvey F. Lodish
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Q
Online Access:https://doaj.org/article/cc5b7658df0d48e1aa16746d22081aea
Tags: Add Tag
No Tags, Be the first to tag this record!